Bristol-Myers Squibb (New York) and Corgentech (South San Francisco, California), a privately held biotechnology company, have entered into an agreement to jointly develop and commercialize Corgentechs E2F Decoy (edifoligide sodium), a first-of-its-kind E2F Decoy treatment currently in Phase III development for the prevention of vein graft failure following coronary artery bypass graft (CABG) and peripheral artery bypass graft surgery.
Browse by Speciality Area